• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Alliance Fellows

2026 Alliance Fellows

The Alliance Fellows Program (formerly Global Research Ambassadors) is a virtual learning and engagement program for people impacted by ALS/MND worldwide who want to deepen their understanding of ALS/MND research, treatment development, and advocacy.

Through self-directed online learning and interactive live sessions, participants build the knowledge, skills, and confidence to engage more meaningfully in research and advocacy conversations within the global ALS/MND community.

2026 Applications Are Now Closed

Thank you to everyone who applied for the 2026 Alliance Fellows Program.

2026 Program Details

Delivery
Fully virtual, using Zoom and an online learning platform
Duration
Four-week program delivered between September 21 and October 23 (dates tentative)
Pre-session learning
Approximately 1.5 hours of individual online learning and preparation before each live session
Live sessions
Nine 90-minute interactive sessions delivered across the program

The program uses a blended learning approach combining self-paced learning with live interactive sessions. Participants engage with expert faculty and peers through discussions, practical exercises, case studies, and collaborative activities.

Live session times will vary to support participation across time zones. Sessions may be scheduled at different times throughout the day, and recordings will be available for participants who are unable to attend live.

Who Can Apply

The Alliance Fellows Program is designed for people with a personal connection to ALS/MND and an interest in research, advocacy, and learning.

You are encouraged to apply if you are:

  • Living with ALS/MND
  • A current or former caregiver
  • An ALS/MND gene carrier without a diagnosis
  • A family member
  • Another member of the ALS/MND community with a strong interest in research and advocacy

Each applicant must submit a separate application.

What You’ll Learn and Gain

The program builds understanding of ALS/MND research and treatment development, clinical trials, scientific communication, research ethics, informed consent, and the important role lived experience plays in shaping research and advocacy.

Participants leave the program with:

  • A stronger understanding of ALS/MND research and treatment development
  • Greater confidence discussing scientific developments
  • Practical tools for advocacy and community engagement
  • Connections with researchers, clinicians, and peers from around the world
  • Recognition as an Alliance Fellow

After Completing the Program

Participants who complete the program receive a certificate of completion, an Alliance Fellow social media badge, recognition through Alliance communications, and opportunities to continue engaging through the Global ALS/MND Experience Network (GAMEN).

A Global Learning Community

One of the program’s greatest strengths is the global community it creates, connecting people affected by ALS/MND across countries, experiences, and perspectives. Bringing lived experience into research conversations can strengthen advocacy, deepen understanding of community priorities, and contribute to more meaningful research.

What Participation Involves

Participants should be interested in learning about ALS/MND research and treatment development, willing to actively participate in discussions and learning activities, and interested in connecting with others across the global ALS/MND community.

To participate, you will need a device with internet access and a webcam, time to attend most live sessions or watch recordings, and a willingness to learn and contribute to discussions.

If selected, participants are expected to review materials in advance, participate actively in sessions, and share what they learn with their communities following the program.

Primary Sidebar

  • Lachlan Terry, Australia

    Lachlan Terry, Australia

  • Roy Taylor, Ireland

    Roy Taylor, Ireland
    roy

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Frank Taylor, USA

    Frank Taylor, USA

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Jorge Melo, Brazil

    Jorge Melo, Brazil

  • Motoko Ogasawara, Japan

    Motoko Ogasawara, Japan

  • Shay Rishoni, Israel

    Shay Rishoni, Israel

  • Orly Dichoso, Canada

    Orly Dichoso, Canada

  • Phil Rossall, UK

    Phil Rossall, UK

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • H. Todd Kelly, USA

    H. Todd Kelly, USA

  • Jack Buzby, USA

    Jack Buzby, USA

  • David Watson, Scotland

    David Watson, Scotland

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Camilla Heiberg Freiberg, Denmark

    Camilla Heiberg Freiberg, Denmark

  • Danny Reviers, Belgium

    Danny Reviers, Belgium

  • Michel Perrozzo, France

    Michel Perrozzo, France

  • Brian Lovell, Australia

    Brian Lovell, Australia

  • Imelda Arenas, Colombia

    Imelda Arenas, Colombia

  • Sally Pauls, USA

    Sally Pauls, USA

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Liam Dwyer, England

    Liam Dwyer, England

  • Paul Launer, USA

    Paul Launer, USA

  • Jan Zuring, Netherlands

    Jan Zuring, Netherlands

  • Vincent Bourque, Canada

    Vincent Bourque, Canada
    vincent_bourque

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Angela Jansen, Germany

    Angela Jansen, Germany

  • Bruno Leanza Mantegna, Italy

    Bruno Leanza Mantegna, Italy

  • Horacio Fritzer, Argentina

    Horacio Fritzer, Argentina

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Ada Garrido Benavidez, Mexico

    Ada Garrido Benavidez, Mexico

  • Ana María Zavala, Mexico

    Ana María Zavala, Mexico

  • Steve Gallagher, Canada

    Steve Gallagher, Canada
    Picture1

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Animesh Kumar, India

    Animesh Kumar, India

  • Cassio Fernando da Silva, Brazil

    Cassio Fernando da Silva, Brazil

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Stephanie Christiansen Hall, Canada

    Stephanie Christiansen Hall, Canada

  • Feng Gin Sun, China

    Feng Gin Sun, China

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • JP

    JP

  • Charlie Dourney, USA

    Charlie Dourney, USA

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Olga, Argentina

    Olga, Argentina

  • Sanjay Kumar Srivastava, India

    Sanjay Kumar Srivastava, India

  • Norm MacIsaac, Canada

    Norm MacIsaac, Canada

  • Bayley, Australia

    Bayley, Australia

  • Ching-Liang Chu, Taiwan

    Ching-Liang Chu, Taiwan

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login